KRAS and neoplasm: The worse prognosis in subjects whose tumor was submitted for KRAS and BRAF mutation analysis compared with those not analyzed could be explained by a need for more antitumor treatment in addition to CRS and HIPEC, where patients with unfavorable prognostic signs are selected for mutation analysis.